Dianthus Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marino Garcia
- Full Time Employees
- 92
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7 Times Square New York NY United States of America 10036
- IPO Date
- Jun 21, 2018
- CIK
- 0001690585
- Website
- dianthustx.com
- Similar Companies
- Business
- Dianthus Therapeutics, Inc. Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company that develops next-generation antibody therapeutics targeting the complement system and related immune pathways for patients with severe autoimmune diseases. Founded in 2019 and headquartered in New York City with additional offices in Waltham, Massachusetts, the company advances a pipeline featuring its lead candidate claseprubart (DNTH103), an investigational, long-acting monoclonal antibody engineered with YTE half-life extension technology for selective inhibition of active C1s in the classical complement pathway, enabling self-administered subcutaneous dosing as infrequently as every two or four weeks; and DNTH212, an investigational extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production while inhibiting BAFF/APRIL signaling to suppress B cell function, also designed for infrequent self-administration every four weeks. Claseprubart targets neuromuscular disorders driven by classical pathway activation, including generalized myasthenia gravis in a Phase 3 trial initiating in 2026, chronic inflammatory demyelinating polyneuropathy with an accelerated Phase 3 interim analysis in Q2 2026, and multifocal motor neuropathy with Phase 2 top-line data expected in 2H 2026; DNTH212 advances in a two-part Phase 1 study in China for healthy volunteers and systemic lupus erythematosus patients initiating by year-end 2025, with top-line healthy volunteer data in 2H 2026. Recent developments include positive Phase 2 MaGic trial results for claseprubart in generalized myasthenia gravis reported in September 2025, demonstrating statistically significant improvements in key efficacy measures versus placebo with favorable safety; an exclusive license agreement in October 2025 with Nanjing Leads Biolabs Co., Ltd. for DNTH212 involving up to $38 million upfront and near-term payments plus up to $962 million in milestones and royalties outside Greater China; closure of an upsized $288 million public offering in September 2025; and a pro forma cash position of approximately $525 million as of September 30, 2025, supporting operations into 2028.
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics to Participate in Two Investor Conferences
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?